10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025.Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023. In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Geno ...